Cartesian Therapeutics Inc
RNAC12.090USD
-0.240-1.95%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
313.57MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cartesian Therapeutics Inc Unternehmen
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Unternehmensinformationen
BörsenkürzelRNAC
Name des UnternehmensCartesian Therapeutics Inc
IPO-datumJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Anzahl der mitarbeiter66
WertpapierartOrdinary Share
GeschäftsjahresendeJun 22
Addresse7495 New Horizon Way
StadtFREDERICK
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl21703
Telefon13013488698
Websitehttps://www.cartesiantherapeutics.com/
BörsenkürzelRNAC
IPO-datumJun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Independent Director
Independent Director
3.82K
-14.03%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
Aktionäre
Aktionäre
Anteil
Springer Timothy A
33.28%
Seven One Eight Three Four Irrevocable Trust
17.55%
Fidelity Management & Research Company LLC
9.02%
MPM BioImpact LLC
3.05%
Singer (Michael S.)
2.72%
Other
34.38%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
39.94%
Corporation
20.08%
Investment Advisor
18.12%
Investment Advisor/Hedge Fund
5.70%
Hedge Fund
1.47%
Research Firm
0.19%
Insurance Company
0.10%
Bank and Trust
0.10%
Pension Fund
0.03%
Other
14.26%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
206
22.28M
85.84%
-1.26M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
2023Q1
272
3.43M
67.38%
-196.84K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Springer Timothy A
8.64M
33.28%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.55%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.34M
9.02%
-83.30K
-3.44%
Mar 31, 2025
MPM BioImpact LLC
790.78K
3.05%
+69.64K
+9.66%
Mar 31, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
TAS Partners, L.L.C.
656.51K
2.53%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
608.03K
2.34%
+1.49K
+0.25%
Mar 31, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
-8.96K
-1.57%
Mar 31, 2025
The Vanguard Group, Inc.
503.54K
1.94%
+74.06K
+17.24%
Mar 31, 2025
Kalayoglu (Murat)
502.42K
1.94%
-8.88K
-1.74%
Apr 14, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ALPS Medical Breakthroughs ETF
0%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.91%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
ProShares Ultra Nasdaq Biotechnology
Anteil0.03%
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
Global X Russell 2000 Covered Call ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
ALPS Medical Breakthroughs ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Datum
Art
Verhältnis
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
Mar 28, 2024
Merger
30<1
